EnteroMedics (RSLS) Getting Somewhat Positive Media Coverage, Accern Reports
Press coverage about EnteroMedics (NASDAQ:RSLS) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. EnteroMedics earned a news impact score of 0.06 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 45.4634649186866 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
EnteroMedics (NASDAQ RSLS) opened at $1.32 on Thursday. EnteroMedics has a 12 month low of $1.23 and a 12 month high of $30.41.
EnteroMedics (NASDAQ:RSLS) last released its quarterly earnings results on Tuesday, November 14th. The medical device company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.77). The firm had revenue of $0.36 million for the quarter. EnteroMedics had a negative return on equity of 104.23% and a negative net margin of 4,509.61%. sell-side analysts predict that EnteroMedics will post -1.97 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “EnteroMedics (RSLS) Getting Somewhat Positive Media Coverage, Accern Reports” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/12/21/enteromedics-rsls-getting-somewhat-positive-media-coverage-accern-reports.html.
EnteroMedics Company Profile
ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Ratings for EnteroMedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics and related companies with MarketBeat.com's FREE daily email newsletter.